Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Parakeratosis and Porokeratosis.
MVD encodes mevalonate diphosphate decarboxylase (400 aa). Catalyzes the ATP dependent decarboxylation of (R)-5-diphosphomevalonate to form isopentenyl diphosphate (IPP). Highest expression in Brain Cerebellum (66.6 TPM) and Cells EBV-transformed lymphocytes (65.2 TPM).
Porokeratosis 7, multiple types is associated with mutations in the MVD gene on chromosome 16.
The MVD protein participates in SREBP1A,2:MVD gene, MVD decarboxylates MVA5PP to IPPP, and Expression of Diphosphomevalonate Decarboxylase (MVD) pathways.
MVD is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
Genetic testing for MVD is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for porokeratosis 7, multiple types.
1 publication has been identified in PubMed for porokeratosis 7, multiple types. Research spans Review / Meta-Analysis (100%).
Loh CH (2024). [PMID: 39387668](https://pubmed.ncbi.nlm.nih.gov/39387668/). *Acta Derm Venereol*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 9:39 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center